Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Shusen Wang et al.|BMJ|2023Cited by 82
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trialTong Li, Qingyuan Zhang, Yang Luo et al.|Nature Communications|2025Cited by 10
Abstract PO1-27-01: Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 TrialQingyuan Zhang, Qingshan Li, Shusen Wang et al.|Cancer Research|2024Cited by 0
A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Updated interim analysis from the NER-Tree study.Xiaojia Wang, Jin Zhang, Xinlan Liu et al.|Journal of Clinical Oncology|2025Cited by 0